133 related articles for article (PubMed ID: 17452128)
1. Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study.
Sadick N; Thomas L
Heart Lung Circ; 2007 Jun; 16(3):200-6. PubMed ID: 17452128
[TBL] [Abstract][Full Text] [Related]
2. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy.
Hoigné P; Attenhofer Jost CH; Duru F; Oechslin EN; Seifert B; Widmer U; Frischknecht B; Jenni R
Int J Cardiol; 2006 Aug; 111(3):413-22. PubMed ID: 16307805
[TBL] [Abstract][Full Text] [Related]
3. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
4. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.
Weidemann F; Breunig F; Beer M; Sandstede J; Störk S; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
Eur Heart J; 2005 Jun; 26(12):1221-7. PubMed ID: 15728649
[TBL] [Abstract][Full Text] [Related]
5. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
6. [Four cases of Fabry's disease mimicking hypertrophic cardiomyopathy].
Tanaka H; Adachi K; Yamashita Y; Toshima H; Koga Y
J Cardiol; 1988 Sep; 18(3):705-18. PubMed ID: 2977798
[TBL] [Abstract][Full Text] [Related]
7. Stress echocardiography: abnormal response of tissue Doppler-derived indices to dobutamine in the absence of obstructive coronary artery disease in patients with chronic renal failure.
Jassal DS; Neilan TG; Picard MH; Wood MJ
Echocardiography; 2007 Jul; 24(6):580-6. PubMed ID: 17584197
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
9. Cardiac manifestations of Anderson-Fabry disease in children and adolescents.
Kampmann C; Wiethoff CM; Whybra C; Baehner FA; Mengel E; Beck M
Acta Paediatr; 2008 Apr; 97(4):463-9. PubMed ID: 18363956
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.
Lobo T; Morgan J; Bjorksten A; Nicholls K; Grigg L; Centra E; Becker G
Intern Med J; 2008 Jun; 38(6):407-14. PubMed ID: 18613897
[TBL] [Abstract][Full Text] [Related]
11. Altered myocardial motion pattern in Fabry patients assessed with CMR-tagging.
Rutz AK; Juli CF; Ryf S; Widmer U; Kozerke S; Eckhardt BP; Boesiger P
J Cardiovasc Magn Reson; 2007; 9(6):891-8. PubMed ID: 18066749
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
13. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
14. Diastolic function abnormalities in rheumatoid arthritis: relation with duration of disease.
Udayakumar N; Venkatesan S; Rajendiran C
Singapore Med J; 2007 Jun; 48(6):537-42. PubMed ID: 17538753
[TBL] [Abstract][Full Text] [Related]
15. Influence of chronic renal insufficiency on left ventricular diastolic function in hypertensives without left ventricular hypertrophy.
Nardi E; Cottone S; Mulè G; Palermo A; Cusimano P; Cerasola G
J Nephrol; 2007; 20(3):320-8. PubMed ID: 17557265
[TBL] [Abstract][Full Text] [Related]
16. Incremental value of measuring the time difference between onset of mitral inflow and onset of early diastolic mitral annulus velocity for the evaluation of left ventricular diastolic pressures in patients with normal systolic function and an indeterminate E/E'.
Min PK; Ha JW; Jung JH; Choi EY; Choi D; Rim SJ; Jang Y; Shim WH; Cho SY; Chung N
Am J Cardiol; 2007 Jul; 100(2):326-30. PubMed ID: 17631092
[TBL] [Abstract][Full Text] [Related]
17. [Cardiac manifestations in Fabry disease].
Lappegård KT; Aass H
Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2395-6. PubMed ID: 11475223
[TBL] [Abstract][Full Text] [Related]
18. Misleading terms in Anderson-Fabry disease.
Weidemann F; Strotmann JM; Breunig F; Niemann M; Maag R; Baron R; Eggert AO; Wanner C
Eur J Clin Invest; 2008 Mar; 38(3):191-6. PubMed ID: 18257782
[TBL] [Abstract][Full Text] [Related]
19. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
20. Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and strain rate imaging.
Shim CY; Park S; Choi EY; Kang SM; Cha BS; Ha JW; Rim SJ; Lee HC; Chung N
Metabolism; 2008 Apr; 57(4):448-52. PubMed ID: 18328343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
